Calliditas Therapeutics AB

Developing global, high-value products for patients with significant unmet medical needs in niche indications

Find out more about us

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Partnering

Find out more about potential partnering opportunities.